Ligand Pharmaceuticals Incorporated ( LGND) - Key Metrics
LGND Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $3.17 | $2.42 | $1.20 | $1.20 |
| 2026Q1 | $2.60 | -$0.67 | $2.45 | $2.44 |
| 2025Q4 | $3.02 | $2.27 | $2.32 | $2.32 |
| 2025Q3 | $5.96 | $6.06 | $0.68 | $0.68 |
| 2025Q2 | $2.46 | $0.25 | $0.82 | $0.81 |
LGND Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | 32.65 |
| 2026Q1 | 0% | -74.50 |
| 2025Q4 | 0% | 20.82 |
| 2025Q3 | 0% | 7.39 |
| 2025Q2 | 0% | 113.68 |
LGND Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q2 | 0.38% | 0% |
| 2026Q1 | 1.22% | 0% |
| 2025Q4 | 1.23% | 0% |
| 2025Q3 | 0.38% | 0% |
| 2025Q2 | 0.71% | 0% |
LGND
Price: $294.60
52 week price:
Payout Ratio Range:
Earnings Per Share: 9.87 USD
P/E Ratio: 29.71
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 186100
Ebitda: 19.2 millionMarket Capitalization: 5.8 billion